Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 6, 2015, Pages 1237-1245

  D'Alessandro, Rosalba ^a,b   Refolo, Maria Grazia ^a,b   Lippolis, Catia ^a,b   Carella, Nicola ^a,b   Messa, Caterina ^a,b   Cavallini, Aldo ^a,b   Carr, Brian Irving ^a,b  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Epidermal growth factor; HCC cells; Platelets; Regorafenib

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; REGORAFENIB; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; ERLOTINIB HYDROCHLORIDE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PYRIDINES; QUINAZOLINES;

EID: 84929966274     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2751-6     Document Type: Article

References (35)

1. Levin J, Conley CL (1964) Thrombocytosis associated with malignant disease. Arch Intern Med 114:497-500
2. Stone RL, Nick AM, McNeish IA et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366:610-618
3. Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576-590
4. Holmes CE, Levis JE, Ornstein DL (2009) Activated platelets enhance ovarian cancer cell invasion in acellular model of metastasis. Clin Exp Metastasis 26:653-661
5. Steller EJ, Raats DA, Koster J et al (2013) PDGFRB promotes liver metastasis Formation of mesenchymal-like colorectal tumor cells. Neoplasia 15:204-207
6. Hwang SJ, Luo JC, Li CP et al (2004) Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 10:2472-2477
7. Carr BI, Guerra V (2013) Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 58:1790-1796
8. Carr BI, Guerra V, Pancoska P (2012) Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology 83:339-345
9. Carr BI, Guerra V (2014) Features of massive hepatocellular carcinomas. Eur J Gastroenterol Hepatol 26:101-108
10. Carr BI, Cavallini A, D'Alessandro R et al (2014) Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 14:351
11. D'Alessandro R, Refolo MG, Lippolis C et al (2014) Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer 14:351
12. Refolo MG, D'Alessandro R, Lippolis C et al (2014) Modulation of doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates. Anticancer Agents Med Chem 14:1154-1160
13. Buergy D, Wenz F, Groden C, Brockmann MA (2012) Tumor-platelet interaction in solid tumors. Int J Cancer 130:2747-2760
14. Song S, Wientjes MG, Gan Y, Au JL (2000) Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 97:8658-8663
15. Shen K, Cui D, Sun L, Lu Y, Han M (2012) Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem 113:2086-2089
16. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG (2010) Metformin: taking away the candy for cancer? Eur J Cancer 46(13):2369-2380
17. Atzori F, Traina TA, Ionta MT, Massidda B (2009) Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol 4:255-266
18. Kina S, Phonaphonh T, Liang F et al (2013) PDGFα receptor is a mediator for cisplatin-induced Met expression. Eur J Pharmacol 699:227-232
19. Zhou T, Duan J, Wang Y et al (2012) Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol 33:1299-1306
20. Peer D, Dekel Y, Melikhov D, Margalit R (2004) Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64:7562-7569
21. Fuchs BC, Hoshida Y, Fujii T et al (2014) Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology 59:1577-1590
22. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2:329-333
23. Carr BI, D'Alessandro R, Refolo MG et al (2013) Effects of low concentrations of Regorafenib and Sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. J Cell Physiol 228:1344-1350
24. Fan FT, Shen CS, Tao L et al (2014) PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation. Asian Pac J Cancer Prev 15:1961-1970
25. Hu Z, Du J, Yang L et al (2012) GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cells. PLoS One 7:e38777
26. Schallmoser K, Bartmann C, Rohde E et al (2007) Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 47:1436-1446
27. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A (2004) An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signaling in hepatocarcinogenesis and in the resistance of HCC cells against drug-induced apoptosis. Biochem Pharmacol 68:1003-1015
28. Liang C, Chen W, Zhi X (2013) Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a. Mol Cancer 9:12-14
29. French DM, Lin BC, Wang M et al (2012) Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 7:e36713
30. Radziwon-Balicka A, Medina C, O'Driscoll L et al (2012) Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol 167:787-804
31. Gilbert LA, Hemann MT (2011) Chemotherapeutic resistance: surviving stressful situations. Cancer Res 71:5062-5066
32. Tian X, Hao K, Qin C, Xie K, Xie X, Yang Y (2013) Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer. Dig Dis Sci 58:2705-2712
33. Huang P, Xu X, Wang L, Zhu B, Wang X, Xia J (2014) The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. J Cell Mol Med 18:218-230
34. Carr BI, Cavallini A, Lippolis C et al (2013) Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 228:292-297
35. D'Alessandro R, Refolo MG, Lippolis C et al (2013) Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol 72:869-877